ObjectiveTo investigate the potential role of protease-activated receptor 2 (PAR2) in the prognosis of hepatocellular carcinoma (HCC).MethodsA total of 202 HCC patients who underwent liver resections were included. Tissue microarray was established with specimens of both HCC and paired adjacent liver tissues. PAR2 expression was detected by immunohistochemistry (IHC) assays.. A semi-quantification method was used to define the expression level of PAR2. The correlations between PAR2 expression and clinical features of patients with HCC was explored. The association of different PAR2 expressions with both overall survival and disease-free survival was analyzed.ResultsResults showed that the expression of PAR2 in HCC tissues was higher than that in paired para-cancerous liver tissues (4.12 ± 3.55 vs. 2.71 ± 2.56, P < 0.001). Higher expression of PAR2 was associated with poor differentiation (P < 0.001) and advanced tumor-node-metastasis stage (P = 0.015). Kaplan-Meier survival analysis indicated that HCC patients with high PAR2 expression had decreased overall survival (P = 0.033) and disease-free survival (P = 0.043) compared to patients with lower PAR2 expression. Multivariate analysis indicated that PAR2 expression (P = 0.032) was a significant independent prognostic factor for both overall survival and disease-free survival (P = 0.032; P = 0.032, respectively).ConclusionOur data revealed that PAR2 expression was increased in HCC. High PAR2 expression was correlated with both decreased overall survival and disease-free survival in patients with HCC. High PAR2 expression indicated a poor prognosis.

中文翻译：

---

蛋白酶激活受体2表达增加表明HBV相关肝细胞癌预后不良

目的探讨蛋白酶激活受体2（PAR2）在肝细胞癌（HCC）预后中的潜在作用。方法纳入202例接受肝切除的HCC患者。使用 HCC 和配对的邻近肝组织样本建立组织微阵列。通过免疫组织化学（IHC）测定检测PAR2的表达。使用半定量方法来定义PAR2的表达水平。探讨 PAR2 表达与 HCC 患者临床特征之间的相关性。分析不同PAR2表达量与总生存期和无病生存期的关系。 结果结果显示，HCC组织中PAR2的表达量高于配对癌旁肝组织（4.12±3.55 vs. 2.71±2.56，P < 0.001）。PAR2 的较高表达与低分化（P < 0.001）和晚期肿瘤淋巴结转移阶段（P = 0.015）相关。Kaplan-Meier生存分析表明，与PAR2表达较低的患者相比，PAR2高表达的HCC患者的总生存期（P = 0.033）和无病生存期（P = 0.043）降低。多变量分析表明，PAR2 表达（P = 0.032）是总生存期和无病生存期（分别为 P = 0.032；P = 0.032）的显着独立预后因素。结论我们的数据显示，HCC 中 PAR2 表达增加。PAR2 的高表达与 HCC 患者的总生存期和无病生存期降低相关。PAR2高表达表明预后不良。